Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Opelconazole - Pulmocide

Next Previous
Drug Profile

Opelconazole - Pulmocide

Alternative Names: PC-945

Latest Information Update: 14 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pulmocide
  • Class Antifungals; Benzamides; Fluorobenzenes; Oxalates; Phenyl ethers; Piperazines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aspergillosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Aspergillosis
  • Phase II Candidiasis

Most Recent Events

  • 07 Jan 2026 Interim adverse events data from the phase-III OPERA-T trial in Aspergillosis (Combination therapy, Treatment-experienced) released by Pulmocide
  • 07 Jan 2026 Pulmocide terminates phase-III OPERA-T trial in Aspergillosis (Combination therapy, Treatment-experienced) in Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, England, France, Germany, Greece, India, Israel, Italy, South Korea, Spain, Taiwan, Thailand, United Kingdom, and USA based on interim analysis of data from the trial and sponsor decision
  • 13 Jan 2025 Opelconazole - Pulmocide receives Orphan Drug status for Aspergillosis in European Union

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top